Clinical Research Directory
Browse clinical research sites, groups, and studies.
2 clinical studies listed.
Filters:
Tundra lists 2 Waldenstrom's Macroglobulinemia Recurrent clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.
This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.
NCT07766421
Evaluation of Iopofosine I 131 vs. R-CD in WM Patients
The goal of this clinical trial is to evaluate whether iopofosine I 131 is more effective than the combination Rituximab-Cyclophosphamide-Dexamethasone (R-CD). The main question the study aims to answer is: • Does iopofosine I 131 work better than R-CD when looking at the length of time during and after the treatment that a patient lives with WM but it does not get worse. Participants will: * Be randomly assigned to received either iopofosine I 131 or R-CD. * If assigned to iopofosine I 131, have it administered via infusion 2 times each cycle for a total of 2 cycles (each cycle is about 3 months long). * If assigned to R-CD, it will be administered for up to six cycles, and each cycle is 3-weeks long * Visit the clinic once every 3 weeks for checkups and testing. * Report any side effects or new medications.
Gender: All
Ages: 18 Years - Any
Updated: 2026-08-14
NCT05952037
A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia
This study will evaluate the safety and efficacy of the BCL2 inhibitor sonrotoclax (BGB-11417) in participants with relapsed/refractory Waldenström's Macroglobulinemia (R/R WM) and in combination with zanubrutinib in adult participants with previously untreated WM.
Gender: All
Ages: 18 Years - Any
Updated: 2026-01-02
37 states